{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:12:40Z","timestamp":1755216760132,"version":"3.43.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>Therapeutic options for sickle cell disease (SCD) have increased recently as well as the development of updated national guidelines. It is not known how these options are being offered or to what degree guidelines are incorporated into clinical practice. This study aimed to describe practice patterns for pediatric hematologists regarding the use of disease-modifying and potentially curative therapies for SCD. A 9-section, cross-sectional electronic survey was disseminated during a 3-month period via SurveyMonkey, to members of the American Society of Pediatric Hematology\/Oncology Hemoglobinopathy Special Interest Group (ASPHO HSIG). A total of 88 physician members of the ASPHO HSIG were surveyed. Ninety percent of respondents (72\/80) start hydroxyurea routinely in patients with HbSS and HbS\u03b2<jats:sup>0<\/jats:sup> thalassemia, regardless of disease severity. Laboratory monitoring was recommended every 3 months for stable dosing in 63.8% (51\/80). New therapies were recommended for patients on hydroxyurea who were still experiencing SCD complications: L-glutamine 68.5% (37\/54) or crizanlizumab 93.1% (54\/58). Voxelotor was recommended for patients on hydroxyurea with low hemoglobin in 65.1% (43\/66) of cases. Matched sibling transplant was considered for any disease severity by 55.1% (38\/69). Gene therapy trials are offered on-site by 29% (20\/69). Our study demonstrated the enhanced utilization of hydroxyurea while revealing the unexplored potential of other disease-modifying therapies in SCD. These findings underscore the importance of continued knowledge acquisition about the long-term efficacy of new medical therapies and addressing barriers to the use of proven therapies and guide the development of future studies of optimal SCD management.<\/jats:p>","DOI":"10.1097\/mph.0000000000002869","type":"journal-article","created":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T16:01:13Z","timestamp":1715184073000},"page":"e277-e283","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-modifying and Potentially Curative Therapies"],"prefix":"10.1097","volume":"46","author":[{"given":"Luisanna M.","family":"S\u00e1nchez","sequence":"first","affiliation":[{"name":"Indiana Hemophilia and Thrombosis Center, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry","family":"Morrone","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Frei-Jones","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology, UTHealth Joe R. and Teresa Lozano Long School of Medicine-San Antonio, San Antonio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Titilope A.","family":"Fasipe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Hematology\/Oncology, Texas Children\u2019s Hospital, Baylor College of Medicine, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"issue":"4 suppl","key":"R1-20250804","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.21570","article-title":"The number of people with sickle-cell disease in the United States: national and state estimates","volume":"85","author":"Brousseau","year":"2010","journal-title":"Am J Hematol"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle cell disease: a review","volume":"328","author":"Kavanagh","year":"2022","journal-title":"JAMA"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM200006223422502","article-title":"Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group","volume":"342","author":"Vichinsky","year":"2000","journal-title":"N Engl J Med"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"e1915374","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw Open"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"2333794X19847026","DOI":"10.1177\/2333794X19847026","article-title":"Barriers to pediatric sickle cell disease guideline recommendations","volume":"6","author":"Cabana","year":"2019","journal-title":"Glob Pediatr Health"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ajh.26063","article-title":"Impact of sickle cell disease on patients\u2019 daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY)","volume":"96","author":"Osunkwo","year":"2021","journal-title":"Am J Hematol"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/hemato2040048","article-title":"Barriers and facilitators of use of hydroxyurea among children with sickle cell disease: experiences of stakeholders in Tanzania","volume":"2","author":"Kilonzi","year":"2021","journal-title":"Hemato"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"921432","DOI":"10.3389\/fgene.2022.921432","article-title":"Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative","volume":"13","author":"Treadwell","year":"2022","journal-title":"Front Genet"},{"issue":"suppl 1","key":"R12-20250804","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2018-160","article-title":"Greater barriers to hydroxyurea (HU) associated with poorer health related quality of life (HRQL) in youth with sickle cell disease","volume":"132","author":"Smaldone","year":"2018","journal-title":"Blood"},{"key":"R13-20250804","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1182\/blood.V116.21.255.255","article-title":"Understanding provider barriers to hydroxyurea use for pediatric sickle cell disease","volume":"116","author":"Oyeku","year":"2010","journal-title":"Blood"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1056\/NEJMoa2000146","article-title":"Hydroxyurea dose escalation for sickle cell anemia in Sub-Saharan Africa","volume":"382","author":"John","year":"2020","journal-title":"N Engl J Med"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1182\/blood-2009-04-146852","article-title":"How I use hydroxyurea to treat young patients with sickle cell anemia","volume":"115","author":"Ware","year":"2010","journal-title":"Blood"},{"key":"R17-20250804","first-page":"1550","article-title":"Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial. Pediatric Hydroxyurea Group","volume":"94","author":"Kinney","year":"1999","journal-title":"Blood"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1542\/peds.2008-0441","article-title":"Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children","volume":"122","author":"Strouse","year":"2008","journal-title":"Pediatrics"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1182\/blood.V97.11.3628","article-title":"Five years of experience with hydroxyurea in children and young adults with sickle cell disease","volume":"97","author":"Ferster","year":"2001","journal-title":"Blood"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-12-4973","article-title":"Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study","volume":"106","author":"Hankins","year":"2005","journal-title":"Blood"},{"key":"R21-20250804","first-page":"125","article-title":"Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes","volume":"91","author":"de Montalembert","year":"2006","journal-title":"Haematologica"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2017-06-788935","article-title":"Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM): a trial for children with sickle cell anemia","volume":"130","author":"Opoka","year":"2017","journal-title":"Blood"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/bloodadvances.2022007679","article-title":"Absolute neutrophil count by Duffy status among healthy Black and African American adults","volume":"7","author":"Merz","year":"2023","journal-title":"Blood Adv"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-Glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1002\/ajh.26021","article-title":"L-glutamine use in adults with sickle cell disease: clinical trials where success meets reality","volume":"96","author":"Ogu","year":"2021","journal-title":"Am J Hematol"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJMe1800976","article-title":"l-Glutamine and the dawn of combination therapy for sickle cell disease","volume":"379","author":"Minniti","year":"2018","journal-title":"N Engl J Med"},{"key":"R29-20250804","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv"},{"key":"R30-20250804","doi-asserted-by":"crossref","first-page":"167 e1","DOI":"10.1016\/j.jtct.2020.10.007","article-title":"Systematic review\/meta-analysis on efficacy of allogeneic hematopoietic cell transplantation in sickle cell disease: an international effort on behalf of the pediatric diseases working party of European Society for Blood and Marrow Transplantation and the Sickle Cell Transplantation International Consortium","volume":"27","author":"Iqbal","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"key":"R32-20250804","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"},{"key":"R33-20250804","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.25401","article-title":"Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study","volume":"94","author":"Krishnamurti","year":"2019","journal-title":"Am J Hematol"},{"key":"R34-20250804","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"key":"R35-20250804","first-page":"1","article-title":"Hematopoietic cell transplantation for sickle cell disease","volume":"8","author":"Krishnamurti","year":"2020","journal-title":"Front Pediatr"},{"key":"R36-20250804","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"N Engl J Med"},{"key":"R37-20250804","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMoa2031054","article-title":"CRISPR-Cas9 gene editing for sickle cell disease and beta-thalassemia","volume":"384","author":"Frangoul","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:06:45Z","timestamp":1754338005000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002869","relation":{},"ISSN":["1077-4114"],"issn-type":[{"type":"print","value":"1077-4114"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"2023-09-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}